Cipla Eu To Invest Eur 15 Million In Ethris, Initiating A Strategic Collaboration

Dec 29, 2022•almost 3 years ago

Amount Raised

€15 Million

Munich

Description

Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) referred to as "Cipla" today announced that its wholly-owned UK subsidiary, Cipla (EU) Limited ("Cipla EU") has signed definitive agreements for equity investment of EUR 15 million in Ethris GmbH ("Ethris"), a global leader in delivering mRNAs directly to the respiratory system including administration by inhalation.

Company Information

Company

Ethris

Location

Munich, Bavaria, Germany

About

Ethris has paved a new path from genes to therapeutic proteins, using its proprietary messenger RNA technology platform to discover, design and develop innovative therapies. With more than a decade as an mRNA pioneer, Ethris is a global leader in delivering stabilised mRNAs directly to the respiratory system via optimised formulation and nebulisation technologies. The company is rapidly advancing its mRNA pipeline of immuno-modulation, protein replacement therapies, and differentiated vaccines against viral infections, with the ultimate goal of improving patients' lives.

Related People

2 contacts

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Cipla Eu To Invest Eur 15 Million In Ethris, Initiating A Strategic Collaboration

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Funding Insights

Company Information